Arvinas Stock

Arvinas Net Margin

The Net Profit Margin of Arvinas (ARVN) as of Aug 19, 2026 is -30.77 %. In the previous year, Net Profit Margin was -75.51 % — a change of -59.25% (higher).

Net Margin

-30.77 %

YoY

-59.25%

Last updated:

Net Profit Margin of Arvinas is 2026 -30.77 % . Net Profit Margin of Arvinas was 2025 -75.51 % . It decreases by -59.25% higher compared to the previous year.

For Arvinas, the net margin of -30.8% is up versus -393.1% a few years ago.

Access this data via the Eulerpool API
Get Free API Key

Arvinas Stock analysis

What does Arvinas do? Arvinas Inc. is a biopharmaceutical company based in New Haven, Connecticut, USA. It was founded in 2013 by Dr. Craig Crews, who also serves as a scientific advisor to the company. The company's mission is to develop innovative therapies based on Proteolysis-Targeting Technology (PROTAC). This technology uses artificially engineered molecules to identify and mark specific proteins in the body, which are then degraded by the body's own enzymes. This approach can treat diseases caused by misfolded or overexpressed proteins. Arvinas' business model is to develop multiple drug candidates based on this platform. The company collaborates with leading academic institutions and biotechnology companies to identify targets that can be reached using PROTAC technology. Additionally, the company has a proprietary pipeline of drug candidates in various stages of clinical development. Arvinas operates in several therapeutic areas, including cancer, immunology, and metabolic disorders. Their drug candidates include ARV-110, a PROTAC targeting the androgen receptor protein (AR), which is a potential therapy for patients with resistant prostate cancer. Similarly, Arvinas' other drug candidates target specific proteins associated with certain diseases. Another drug from the company is ARV-471, an orally administered degrader targeting the estrogen receptor alpha (ERa), which plays a role in breast cancer. ARV-471 is a potential therapy for patients with rare subtypes of breast cancer. Arvinas also has partnerships in various areas of drug development. For example, in collaboration with Pfizer, they are developing ARV-411, a PROTAC targeting the menin-1 protein, which is involved in acute myeloid leukemia. Arvinas also has a partnership with Genentech, a subsidiary of Roche, for the use of PROTAC in the treatment of cancer. Overall, Arvinas is an innovative biopharmaceutical company based on Proteolysis-Targeting Technology, focusing on the development of comprehensive therapeutic approaches. With numerous partnerships and a diverse pipeline, the company is well-positioned to play a significant role in drug development. Arvinas is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arvinas stock

Net Profit Margin of Arvinas is -30.77 % in 2026.

Net Profit Margin of Arvinas changed from -75.51 % to -30.77 %, representing a -59.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Arvinas since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Arvinas with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API
Get Free API Key

Margins — Arvinas

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Arvinas